220 related articles for article (PubMed ID: 23555261)
1. TIM-3 does not act as a receptor for galectin-9.
Leitner J; Rieger A; Pickl WF; Zlabinger G; Grabmeier-Pfistershammer K; Steinberger P
PLoS Pathog; 2013 Mar; 9(3):e1003253. PubMed ID: 23555261
[TBL] [Abstract][Full Text] [Related]
2. Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection.
Elahi S; Niki T; Hirashima M; Horton H
Blood; 2012 May; 119(18):4192-204. PubMed ID: 22438246
[TBL] [Abstract][Full Text] [Related]
3. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.
Yang R; Sun L; Li CF; Wang YH; Yao J; Li H; Yan M; Chang WC; Hsu JM; Cha JH; Hsu JL; Chou CW; Sun X; Deng Y; Chou CK; Yu D; Hung MC
Nat Commun; 2021 Feb; 12(1):832. PubMed ID: 33547304
[TBL] [Abstract][Full Text] [Related]
4. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
Huang YH; Zhu C; Kondo Y; Anderson AC; Gandhi A; Russell A; Dougan SK; Petersen BS; Melum E; Pertel T; Clayton KL; Raab M; Chen Q; Beauchemin N; Yazaki PJ; Pyzik M; Ostrowski MA; Glickman JN; Rudd CE; Ploegh HL; Franke A; Petsko GA; Kuchroo VK; Blumberg RS
Nature; 2015 Jan; 517(7534):386-90. PubMed ID: 25363763
[TBL] [Abstract][Full Text] [Related]
5. Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors.
Okoye I; Xu L; Motamedi M; Parashar P; Walker JW; Elahi S
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33310773
[TBL] [Abstract][Full Text] [Related]
6. CXCR5 and TIM-3 expressions define distinct exhausted T cell subsets in experimental cutaneous infection with
Diupotex M; Zamora-Chimal J; Gajón JA; Bonifaz LC; Becker I
Front Immunol; 2023; 14():1231836. PubMed ID: 37691941
[TBL] [Abstract][Full Text] [Related]
7. Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
Pagliano O; Morrison RM; Chauvin JM; Banerjee H; Davar D; Ding Q; Tanegashima T; Gao W; Chakka SR; DeBlasio R; Lowin A; Kara K; Ka M; Zidi B; Amin R; Raphael I; Zhang S; Watkins SC; Sander C; Kirkwood JM; Bosenberg M; Anderson AC; Kuchroo VK; Kane LP; Korman AJ; Rajpal A; West SM; Han M; Bee C; Deng X; Schebye XM; Strop P; Zarour HM
J Clin Invest; 2022 May; 132(9):. PubMed ID: 35316223
[TBL] [Abstract][Full Text] [Related]
8. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.
Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892
[TBL] [Abstract][Full Text] [Related]
9. HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors.
Muñoz-Muela E; Trujillo-Rodríguez M; Serna-Gallego A; Saborido-Alconchel A; Ruiz-Mateos E; López-Cortés LF; Gutiérrez-Valencia A
Biomed Pharmacother; 2023 Dec; 168():115750. PubMed ID: 37871555
[TBL] [Abstract][Full Text] [Related]
10. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8
Lake CM; Voss K; Bauman BM; Pohida K; Jiang T; Dveksler G; Snow AL
Cell Death Dis; 2021 Apr; 12(4):400. PubMed ID: 33854046
[TBL] [Abstract][Full Text] [Related]
11. The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms.
Shibamiya A; Miyamoto-Nagai Y; Koide S; Oshima M; Rizq O; Aoyama K; Nakajima-Takagi Y; Kato R; Kayamori K; Isshiki Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Takeda Y; Koyama-Nasu R; Chiba T; Honda H; Yokote K; Iwama A; Sakaida E; Mimura N
Cancer Immunol Immunother; 2023 Aug; 72(8):2635-2648. PubMed ID: 37069353
[TBL] [Abstract][Full Text] [Related]
12. Activated Tim-3/Galectin-9 participated in the development of multiple myeloma by negatively regulating CD4 T cells.
Zhang R; Chen S; Luo T; Guo S; Qu J
Hematology; 2024 Dec; 29(1):2288481. PubMed ID: 38108336
[TBL] [Abstract][Full Text] [Related]
13. Expression of Galectin-9-related immune checkpoint receptors in B-cell acute lymphoblastic leukemia.
Akbar A; Asgarian-Omran H; Valadan R; Dindarloo MM; Najafi A; Kahrizi A; Poursheikhani A; Karami H; Naderi M; Sabeti S; Tehrani M
Iran J Basic Med Sci; 2023; 26(12):1468-1474. PubMed ID: 37970435
[TBL] [Abstract][Full Text] [Related]
14. Galectin 7 leads to a relative reduction in CD4+ T cells, mediated by PD-1.
Wu G; Deng W; Chen HY; Cho HJ; Kim J
Sci Rep; 2024 Mar; 14(1):6625. PubMed ID: 38503797
[TBL] [Abstract][Full Text] [Related]
15. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models.
Ma S; Tian Y; Peng J; Chen C; Peng X; Zhao F; Li Z; Li M; Zhao F; Sheng X; Zong R; Li Y; Zhang J; Yu M; Zhu Q; Tian X; Li Y; Neckenig MR; Liu H; Zhan P; Yue X; Wu Z; Gao L; Liang X; Liu X; Li C; Ma C
Sci Transl Med; 2023 Nov; 15(722):eadg6752. PubMed ID: 37967204
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for T cell immunoglobulin and mucin protein 3 and Toxascaris leonina galectin complex.
Han CW; Jeong MS; Lee HN; Hwang EY; Jang SB
Biochem Biophys Res Commun; 2024 Feb; 697():149544. PubMed ID: 38245927
[TBL] [Abstract][Full Text] [Related]
17. Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor.
Hajihassan Z; Mohammadpour Saray M; Yaseri A
Iran Biomed J; 2023 Jul; 27(4):191-8. PubMed ID: 37525418
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3.
Homayouni V; Khanahmad H; Ganjalikhani-Hakemi M; Behdani M; Ghasemi P; Rezaei A
Iran J Biotechnol; 2017; 15(3):166-171. PubMed ID: 29845065
[No Abstract] [Full Text] [Related]
19. Interaction of the Immune System TIM-3 Protein with a Model Cellular Membrane Containing Phosphatidyl-Serine Lipids.
Delova A; Pasc A; Monari A
Chemistry; 2024 Apr; 30(22):e202304318. PubMed ID: 38345892
[TBL] [Abstract][Full Text] [Related]
20. Establishment of novel anti-TIM-3 antibodies interfering with its binding to ligands.
Yan Z; Ma T; Wang X; Yi L; Wei P; Zhang H; Wang J
Heliyon; 2024 Apr; 10(7):e28126. PubMed ID: 38560237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
